The emerging role of IL-23 in asthma and its clinical implications

References

• Wakashin H, Hirose K, Maezawa Y, et al., IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med. 2008;178(10): 1023–1032.
   PubMed Web of Science ®Google Scholar
• Lewkowich IP, Lajoie S, Clark JR, et al. Allergen uptake, activation, and IL-23 production by pulmonary myeloid DCs drives airway hyperresponsiveness in asthma-susceptible mice. PLoS ONE. 2008;3(12):e3879.
   PubMed Web of Science ®Google Scholar
• Peng J, Yang XO, Chang SH, et al. IL-23 signaling enhances Th2 polarization and regulates allergic airway inflammation. Cell Res. 2010;20(1):62–71.
   PubMed Web of Science ®Google Scholar
• Nakajima H, Hirose K. Role of IL-23 and Th17 cells in airway inflammation in asthma. Immune Netw. 2010;10(1):1–4.
   PubMedGoogle Scholar
• Ciprandi G, Cuppari C, Salpietro AM, et al. Serum IL-23 strongly and inversely correlates with FEV1 in asthmatic children. Int Arch Allergy Immunol. 2012;159(2):183–186.
   PubMed Web of Science ®Google Scholar
• Wang N, Brix S, Larsen JM, et al. Innate IL-23/Type 17 immune responses mediate the effect of the 17q21 locus on childhood asthma. Clin Exp Allergy. 2021;51(7):892–901.
   PubMed Web of Science ®Google Scholar
• Husein-ElAhmed H, Steinhoff M. Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence. J Dermatolog Treat. 2021;32(1):1–6.
   PubMedGoogle Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–725.
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699–5708.
   PubMed Web of Science ®Google Scholar
• Li Y, Hua S. Mechanisms of pathogenesis in allergic asthma: role of interleukin-23: IL-23 and allergic asthma. Respirology. 2014;19(5):663–669.
   PubMed Web of Science ®Google Scholar
• Abdollahi E, Tavasolian F, Momtazi-Borojeni AA, et al. Protective role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated diseases: a comprehensive review. J Immunotoxicol. 2016;13(3):286–300.
   PubMed Web of Science ®Google Scholar
• Mosayebian A, Ganjalikhani Hakemi M, Meshkat R, et al. Association between interleukin-23 receptor R381Q Gene. Iran J Allergy Asthma Immunol. 2015;14(4):386–391.
   PubMed Web of Science ®Google Scholar
• Taherian M, Razavi AR, Izad M, et al. The role of interleukin-23 in stability of in vitro T helper-17 cells. Iran J Allergy Asthma Immunol. 2014;13(2):131–137.
   PubMed Web of Science ®Google Scholar
• Al-Ramli W, Préfontaine D, Chouiali F, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123(5):1185–1187.
   PubMed Web of Science ®Google Scholar
• Wang Y-H, Wills-Karp M. The potential role of interleukin-17 in severe asthma. Curr Allergy Asthma Rep. 2011;11(5):388–394.
   PubMed Web of Science ®Google Scholar
• Masaki K, Suzuki Y, Kagawa S, et al. Dual role of interleukin-23 in epicutaneously-sensitized asthma in mice. Allergol Int. 2014;63(1):13–22.
   PubMedGoogle Scholar
• Lee HS, Park D-E, Lee J-W, et al. IL-23 secreted by bronchial epithelial cells contributes to allergic sensitization in asthma model: role of IL-23 secreted by bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2017;312(1):L13–L21.
   PubMed Web of Science ®Google Scholar
• Lee HS, Park D-E, Lee J-W, et al. Critical role of interleukin-23 in development of asthma promoted by cigarette smoke. J Mol Med (Berl). 2019;97(7):937–949.
   PubMed Web of Science ®Google Scholar
• Halwani R, Sultana A, Vazquez-Tello A, et al. Th-17 regulatory cytokines IL-21, IL-23, and IL-6 enhance neutrophil production of IL-17 cytokines during asthma. J Asthma. 2017;54(9):893–904.
   PubMed Web of Science ®Google Scholar
• Ogawa R, Suzuki Y, Kagawa S, et al. Distinct effects of endogenous interleukin-23 on eosinophilic airway inflammation in response to different antigens. Allergol Int. 2015;64:S24–9.
   PubMed Web of Science ®Google Scholar
• Choy DF, Hart KM, Borthwick LA, et al. Th2 and Th17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med. 2015;7(301):301ra129.
   PubMed Web of Science ®Google Scholar
• Newcomb DC, Zhou W, Moore ML, et al. A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol. 2009;182(9):5317–5321.
   PubMed Web of Science ®Google Scholar
• Newcomb DC, Boswell MG, Zhou W, et al. Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production. J Allergy Clin Immunol. 2011;127(4):1006–13.e1–4.
   Web of Science ®Google Scholar
• Lee HS, Park D-E, Lee J-W, et al., Role of interleukin-23 in the development of nonallergic eosinophilic inflammation in a murine model of asthma. Exp Mol Med. 2020;52(1): 10–92.
   Web of Science ®Google Scholar
• Torres T, Vilaça S, Velho G, et al. Etanercept-induced asthma in a psoriatic patient resolving with transition to ustekinumab. Eur J Dermatol. 2012;22(5):696–697.
   PubMed Web of Science ®Google Scholar
• Amarnani A, Rosenthal KS, Mercado JM, et al. Concurrent treatment of chronic psoriasis and asthma with ustekinumab. J Dermatolog Treat. 2014;25(1):63–66.
   PubMed Web of Science ®Google Scholar
• Schmiedeberg K, Rassouli F, von Kempis J, et al. Anti-interleukin-23-directed therapy and the recurrence of severe allergic asthma. Rheumatology. 2022;71(1):63–66
   Google Scholar
• Kalra SS, Chizinga M, Trillo-Alvarez C, et al. Ustekinumab associated chronic eosinophilic pneumonia. J Asthma. 2021;58(12):1670–1674.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, et al., Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11): 1294–1302.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Nair P, Cousins DJ, et al., Risankizumab in severe asthma - a phase 2a, placebo-controlled trial. N Engl J Med. 2021;385(18): 1669–1679.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021;384(19):1800–1809.
   PubMed Web of Science ®Google Scholar
• Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol. 2021;148(3):790–798.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021;385(18):1656–1668.
   PubMed Web of Science ®Google Scholar